Summary of New, Very Promising Drug Has the “Unique Ability To Prevent Malaria”:
Researchers from the University of Copenhagen have studied a new drug to prevent malaria in pregnant women. The new drug, dihydroartemisinin-piperaquine (DP), has shown promising results in preventing malaria. Still, researchers also learned that the existing drug sulfadoxine-pyrimethamine (SP) protects women from sexually transmitted and reproductive tract infections. The study involved under 5,000 pregnant women from Kenya, Tanzania, and Malawi in East Africa. The researchers are now testing whether it is possible to combine the two drugs. However, they acknowledge that getting pregnant women to take two types of medication instead of one may be a challenge.
*****
New Drug Shows Promise in Preventing Malaria in Pregnant Women
Malaria is a deadly infectious disease affecting millions worldwide, particularly pregnant women in sub-Saharan Africa. The disease poses a significant risk to the mother and her unborn child, increasing the risk of premature birth and low birth weight. Unfortunately, the malaria parasite has developed resistance to some antimalarial drugs, making it a serious global health problem. However, according to a study published in the esteemed journal, The Lancet, a new drug has shown promise in preventing malaria in pregnant women.
Testing a New Drug to Prevent Malaria
Researchers from the Centre for Medical Parasitology (CMP) at the University of Copenhagen, in collaboration with the EU-funded international consortium IMPROVE, studied the effectiveness of dihydroartemisinin-piperaquine (DP), a new drug for preventing malaria. The study involved nearly 5,000 pregnant women from Kenya, Tanzania, and Malawi in East Africa.
Some women were treated with DP, while others received the common, recommended drug called sulfadoxine-pyrimethamine (SP). The researchers expected DP to be more effective against malaria than SP, allowing them to advise the World Health Organization (WHO) to replace SP with DP. However, their findings showed that SP protects women from sexually transmitted and reproductive tract infections (STIs and RTIs) and has unexpected benefits for pregnant women.
Combining Two Drugs
The study results are promising, and more tests have been launched to see whether the two drugs, SP and DP, can be combined. However, getting pregnant women to take two types of medication instead of one can be challenging. According to Christentze Schmiegelow, a postdoctoral doctor at CMP, women are often reluctant to take multiple medications due to fear of side effects or negative interactions with other medicines they are taking. In addition, healthcare systems may object to purchasing two drugs instead of one, as SP is cheap and DP is not. Nevertheless, the costs of women and infants falling ill or dying far outweigh any additional expenses.
An Important Contribution to Understanding Measures to Prevent and Treat Malaria
The study is essential to understanding which measures effectively prevent and treat malaria in pregnancy. According to Associate Professor Michael Alifrangis from CMP, the new drug can prevent malaria, and SP unexpectedly benefits pregnant women. The next step is to find a way to combine these two treatments to create a more effective solution for preventing and treating malaria in pregnant women.
In conclusion, the fight against malaria remains a serious global health problem, particularly in sub-Saharan Africa, where pregnant women and infants are especially vulnerable. However, the promising results of this study provide hope that a solution to preventing and treating malaria in pregnant women is within reach. By combining drugs and continuing to conduct further research, researchers and healthcare systems can work together to save the lives of millions of vulnerable women and children worldwide.
Comments are closed